Trial Profile
A double-blind, placebo controlled rial of EGRIFTA in non-HIV patients with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatoheptitis (NASH)
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 18 May 2018
Price :
$35
*
At a glance
- Drugs Tesamorelin (Primary)
- Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- 18 May 2018 New trial record
- 11 May 2018 According to a THeratechnologies media release, the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (NIH) in the United States has awarded a grant to the Massachusetts General Hospital to conduct this trial.